A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom
A phase 1/2 trial of AZD4512 in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.
Overview
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT07123454 by AstraZeneca, with 91 participants planned, started 2025-09-24 and due to reach its primary completion in 2028-03-01. Interventions recorded: AZD4512. Conditions listed: B-cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Shares AZD4512, AstraZeneca.
- TrialSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Shares Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.
- TrialAZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Shares Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.
- TrialStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Shares Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.
- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- TrialA Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly
- TrialA Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- TrialA Study of Carmustine With and Without Ethanol in Subjects With Lymphoma